Introduction {#Sec1}
============

A combined analysis of 54 studies observed a 24% increase in breast cancer risk for current use of oral contraceptives (OCs) and a 16% increase in risk for \<5 years since stopping OC use \[[@CR1]\]; the increase largely disappeared within 10 years after cessation. However, the length of time during which risk remains elevated is uncertain because few studies have assessed long intervals since stopping \[[@CR2],[@CR3]\]. Subsequent studies suggest that long duration of OC use may also increase incident breast cancer risk \[[@CR4]-[@CR13]\]. These studies were based primarily on data from White women.

Gene expression studies have identified at least five intrinsic subtypes of breast cancer, and the most common clinical markers of breast cancer heterogeneity to date have been presence or absence of estrogen receptors (ERs) or progesterone receptors (PRs) and overexpression of human epidermal growth factor receptor 2 (HER2) \[[@CR14]\]. Tumors that are ER-- or triple negative (TN, defined as ER--/PR--/HER2--) have a lower 5-year survival than ER+ tumors \[[@CR15],[@CR16]\], and are more common in African American women than in women of European ancestry \[[@CR17]-[@CR19]\].

Some risk factors, particularly hormone-related factors, appear to differentially associate with specific breast cancer subtype \[[@CR20],[@CR21]\], but evidence on OC use in relation to specific breast cancer subtypes is sparse and the findings are inconsistent \[[@CR22]\]. Some studies find OC use to be associated with increased risk of ER+ and ER-- breast cancer \[[@CR4],[@CR9]\], others with increased risk of ER-- breast cancer only \[[@CR23]\], and yet others observe an association solely for ER+ breast cancer \[[@CR24]\]. With respect to TN breast cancer, null results \[[@CR2],[@CR25]\] and an increased risk \[[@CR23],[@CR26]\] have been observed for OC use.

The objective of the present study was to investigate OC use in relation to molecular subtypes of breast cancer in African American women using data from a large consortium, the African American Breast Cancer Epidemiology and Risk (AMBER) project. In particular, we were able to assess long duration of OC use and recency of use, including intervals as long as 30 years or more since last use.

Methods {#Sec2}
=======

Participating studies and data collection {#Sec3}
-----------------------------------------

The AMBER Consortium has been described in detail elsewhere \[[@CR27]\]. Its purpose is to provide enough data and samples for informative assessment of genetic and nongenetic factors in relation to breast cancer subtypes in African American women. The AMBER Consortium pools data from two large case--control studies, the Carolina Breast Cancer Study (CBCS) and the Women's Circle of Health Study (WCHS), and two large cohort studies, the Black Women's Health Study (BWHS) and the Multiethnic Cohort Study. Owing to missing data on recency of OC use, the Multiethnic Cohort Study was not included in this analysis, whereas data from the BWHS, the CBCS, and the WCHS were included.

The BWHS is a prospective cohort study of 59,000 African American women aged 21 to 69 years at baseline in 1995 \[[@CR28]\]. Participants report data on OC use, other risk factors, and incident disease on biennial questionnaires. Questionnaire follow-up is complete for 80% of the baseline cohort through 2011. New diagnoses of cancer are self-reported on the follow-up questionnaires or identified through linkage with state cancer registries \[[@CR9],[@CR27]\]. For each case, controls were selected from the pool of BWHS participants who had not developed breast cancer at the date of the case's breast cancer diagnosis (index date). Controls were frequency-matched to cases on 5-year age group, geographic region, and most recent questionnaire completed before the matched case diagnosis. Exposure and covariate data from that questionnaire and preceding questionnaires were used for the analysis.

The CBCS is a population-based case--control study of women aged 20 to 74 years in North Carolina conducted from 1993 through 2001 \[[@CR29]\]. Breast cancer cases are identified through the North Carolina Central Cancer Registry. We used data from the first two phases, in which younger and African American cases were oversampled. Cases and controls were sampled using a modification of randomized recruitment. Controls younger than age 65 years were identified from Division of Motor Vehicle lists and controls age 65 years or older were identified from Health Care Financing Administration lists. Controls were frequency-matched to cases on age in 5-year age groups. Exposure and covariate data were collected through in-person interviews with reference to the year before diagnosis (cases) or interview date (controls) \[[@CR29]\]. Response rates were 76% for cases and 55% controls for recruitment of invasive breast cancer cases and matched controls, while response rates were 83% for cases and 65% controls for recruitment of *in situ* breast cancer cases and matched controls \[[@CR29]\].

The WCHS is a population-based case--control study of women aged 20 to 75 years that began in New York in 2003 and currently enrolls participants in New Jersey only \[[@CR30],[@CR31]\]. Breast cancer cases were identified through major hospitals in New York City and through the New Jersey Cancer Registry. Controls were identified through random digit dialing and through community-based recruitment and are frequency matched to cases on age in 5-year age groups \[[@CR31]\]. Exposure and covariate data were collected through in-person interviews with reference to the year before diagnosis (cases) or interview date (controls) \[[@CR30]\]. Response rates were 78.7% in cases and 48.2% in controls \[[@CR32]\].

Each study obtained informed consent from all participants and was approved by the relevant Institutional Review Boards, which are listed in Acknowledgements. Each study prepared a data file that included questionnaire data for a specified set of variables and pathology data from medical records or state cancer registry records. Data were harmonized at the data coordinating center with regular input from each study's principal investigator and data collection staff.

Cases {#Sec4}
-----

Incident cases of breast cancer (primary site codes C500 to C506, C508, and C509 in the *International Classification of Diseases for Oncology*, Third Edition), not including lobular carcinoma *in situ* (8520/2), phyllodes tumors (9020), or Paget's disease (8540/3), were confirmed through medical records and state cancer registries \[[@CR33]\]. Immunohistochemistry results were obtained from hospital pathology records and cancer registry data, and were used to classify cases as ER+, ER--, and TN (ER*--/*PR*--*/HER2--). ER data were available for 72% of cases and PR data were available for 69% of cases. Testing for HER2 has become routine more recently; therefore, HER2 data were available for only 49% of cases. There were no statistically significant differences between women with and without known receptor status by age or OC use. The proportion of ER-- cases (Table [1](#Tab1){ref-type="table"}) are similar to those observed for African American women in other data sources \[[@CR34]-[@CR36]\].Table 1**Characteristics of cases and controls in the AMBER Consortium, by included study (BWHS, CBCS, WCHS)BWHSCBCSWCHSTotalCasesControlsCasesControlsCasesControlsCasesControlsCharacteristics of breast cancer cases**Total1,3138047742,891ER+862 (66)436 (54)550 (71)1,848 (64)ER--451 (34)368 (46)224 (29)1,043 (36)Triple negative155 (12)210 (26)129 (17)494 (17)Age at diagnosis  \< 40 years98 (8)129 (16)87 (11)324 (11) 40 to 49 years385 (29)262 (33)209 (27)856 (30) 50 to 59 years456 (35)190 (24)277 (36)923 (32)  ≥ 60 years374 (29)223 (28)191 (25)788 (27)**Oral contraceptive use among cases and controls**Ever use No525 (40)3,768 (45)392 (49)387 (49)374 (48)477 (49)1,291 (45)4,632 (46) Yes788 (60)4,522 (55)412 (51)398 (51)400 (52)492 (51)1,600 (55)5,412 (54)Recency of OC use  \< 5 years ago182 (14)950 (11)68 (8)52 (7)64 (8)73 (8)314 (11)1,075 (11) 5 to 9 years ago68 (5)464 (6)44 (5)32 (4)36 (5)48 (5)148 (5)544 (5) 10 to 14 years ago77 (6)499 (6)53 (7)59 (8)39 (5)37 (4)169 (6)595 (6) 15 to 19 years ago105 (8)620 (7)95 (12)85 (11)45 (6)52 (5)245 (8)757 (8) 20 to 24 years ago108 (8)692 (8)90 (11)102 (13)47 (6)65 (7)245 (8)859 (9) 25 to 29 years ago124 (9)653 (8)35 (4)46 (6)55 (7)79 (8)214 (7)778 (8)  ≥ 30 years ago124 (9)644 (8)24 (3)21 (3)108 (14)130 (13)256 (9)795 (8)Duration of OC use  \< 5 years316 (24)1,934 (23)159 (20)174 (22)152 (20)207 (21)627 (22)2,315 (23) 5 to 9 years235 (18)1,364 (17)125 (16)123 (16)121 (16)142 (15)481 (17)1,629 (16) 10 to 14 years178 (14)874 (11)81 (11)61 (8)71 (9)75 (8)330 (11)1,010 (10)  ≥ 15 years59 (4)350 (4)47 (6)40 (5)56 (7)68 (7)162 (6)458 (5)Data presented as *n* (%). Total percentages may not add up to 100% due to rounding. Excluding women with unknown duration of OC use and unknown ER status. ER status was unknown for 1,151 breast cancer cases: 90 in CBCS, 308 in WCHS, and 753 in BWHS. AMBER, African American Breast Cancer Epidemiology and Risk; BWHS, Black Women's Health Study; CBCS, Carolina Breast Cancer Study; ER, estrogen receptor; OC, oral contraceptive; WCHS, Women's Circle of Health Study.

Exposure variables {#Sec5}
------------------

### Oral contraceptive use {#Sec6}

The main exposures of interest for the present analyses were self-reported recency of OC use (years since last use) and duration of OC use. Women with a total duration of OC use of less than 1 year were considered to be never users. Recency of OC use was categorized as within the previous 5 years, 5 to 9 years ago, 10 to 14 years ago, 15 to 19 years ago, 20 to 24 years ago, 25 to 29 years ago, or ≥30 years ago. Duration of OC use was categorized as 1 to 4 years, 5 to 9 years, 10 to 14 years, or ≥15 years.

### Covariates {#Sec7}

Self-reported data were available on the following covariates: history of breast cancer in a first-degree female relative (mother, sister, or daughter), age at menarche, parity, age at first birth, lifetime duration of breastfeeding, menopausal status, age at menopause, menopausal female hormone use, height, weight, educational attainment, alcohol consumption, and cigarette smoking. For menopausal status, women who were still menstruating were classified as premenopausal. Women who had experienced a natural menopause or a hysterectomy with bilateral oophorectomy were classified as postmenopausal. Also classified as postmenopausal were women (*n* = 60) whose periods had stopped due to use of mediation, radiation, or chemotherapy for various health conditions other than breast cancer. Women who had a hysterectomy with retention of one or both ovaries were classified as premenopausal if their index age was less than or equal to the age at which 10% of women in their study had reached natural menopause, and as postmenopausal if their index age was greater than or equal to the age at which 90% of women in their study had reached natural menopause; otherwise, these participants were classified as having unknown menopausal status.

Data analysis {#Sec8}
-------------

Polytomous logistic regression models were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the relation of measures of OC use to ER+ and ER-- breast cancer risk. For TN breast cancer risk, polytomous models had three outcomes: TN, ER+, and ER--/not TN. We controlled for age (continuous), study (CBCS, WCHS, BWHS), time period of case diagnosis/control index date (1993 to 1998, 1999 to 2005, 2006 to 2013), family history of breast cancer (yes, no), age at menarche (\<12, 12 to 13, ≥14 years), parity (0, 1, 2, ≥3 births), age at first birth (\<20, 20 to 24, ≥25 years), lactation (never, ever), menopausal status and age at menopause (premenopausal, \<45, 45 to 49, 50 to 54, ≥55 years), female hormone use (0, \<5, ≥5 years of use), body mass index (weight in kilograms divided by height in meters squared; \<18.5, 18.5 to 24.9, 25.0 to 29.9, 30.0 to 34.9, ≥35.0 kg/m^2^), educational attainment (\<12, 12, 13 to 15, 16, \>16 years), alcohol consumption (\<1, 1 to 6, ≥7 drinks per week), smoking status (0, \<10, 10 to 19, ≥20 pack-years), and geographic region (New Jersey, other Northeast, South, Midwest, West). We used the missing indicator method to handle missing data. For menopausal status, 8.8% of women had missing data; for each of the other covariates, fewer than 2% had missing data. To test for trend across categories of OC duration or OC recency, the ordinal variable was treated as a continuous variable in the regression model. Trend tests were carried out among OC users only. To examine potential differences by subtype, we carried out case--case analyses, in which ORs were computed for the relation of OC use to ER-- relative to ER+ breast cancer. Effect modification was explored through stratification by age, menopausal status, body mass index, and parity. Interaction on the multiplicative scale was tested by the likelihood ratio test, comparing models with and without multiplicative interaction terms. Analyses were performed using SAS 9.2 statistical software (SAS Institute Inc., Cary, NC, USA).

In addition to the main analyses, which were carried out in pooled data, study-specific ORs were calculated and combined in a random-effects meta-analysis. The Cochran's Q statistic was used to test for heterogeneity \[[@CR37]\]. Meta-analyses were performed using Stata/SE 11.2 statistical software (StataCorp LP, College Station, TX, USA).

Results {#Sec9}
=======

Characteristics of cases and controls are presented in Table [1](#Tab1){ref-type="table"}. Among the 2,891 cases, 1,043 (36%) had tumors that were classified as ER-- and 1,848 (64%) were classified as ER+ (Table [1](#Tab1){ref-type="table"}). In addition, 494 of the ER-- cases were TN breast cancer. The mean age at diagnosis was 52.7, with 11.2% of cases diagnosed before age 40 and 27.3% diagnosed at age 60 or older. OC use was similar across the three participating studies.

Table [2](#Tab2){ref-type="table"} presents analyses of OC use in relation to ER+ and ER-- breast cancer. Ever OC use was positively associated with both ER+ (OR = 1.15, 95% CI = 1.02 to 1.28) and ER-- (OR = 1.24, 95% CI = 1.07 to 1.43) breast cancer. There was a significant dose--response association with recency of OC use for both ER+ and ER-- breast cancer (*P* trend \<0.01 and *P* trend = 0.05, respectively). The strongest associations were for OC use within the previous 5 years (OR = 1.46, 95% CI = 1.18 to 1.81 for ER+ breast cancer and OR = 1.57, 95% CI = 1.22 to 2.03 for ER-- breast cancer). For ER+ breast cancer, the ORs were elevated through 15 to 19 years since last use and the estimate for 15 to 19 years was statistically significant (OR = 1.29, 95% CI = 1.04 to 1.58). For ER-- breast cancer, the pattern was less consistent; the OR declined to 1.07 (95% CI =, 0.83 to 1.37) at 20 to 24 years since last use, but there was a statistically significant elevation at 25 to 29 years since last use (OR = 1.41, 95% CI = 1.09 to 1.81). Risk of ER-- cancer increased with increasing duration of OC use, with ORs of 1.43 (95% CI = 1.13 to 1.80) and 1.54 (95% CI = 1.15 to 2.06) for 10 to 14 and ≥15 years duration, respectively. For ER+ breast cancer, the OR for 10 to 14 years duration was elevated (1.35, 95% CI = 1.12 to 1.61) but the estimate for ≥15 years was approximately 1.00. Among recent users, risk increased with increasing duration of OC use for both ER+ and ER-- cancer. The OR for ≥10 years of use that continued into the 5 years before diagnosis or index date was 1.65 (95% CI = 1.27 to 2.15) for ER+ cancer and 1.73 (95% CI = 1.26 to 2.37) for ER-- cancer. The corresponding estimates for ≥10 years of use that ended at least 20 years previously was 0.88 (95% CI = 0.65 to 1.19) for ER+ cancer and 1.50 (95% CI = 1.03 to 2.17) for ER-- cancer.Table 2**Oral contraceptive use in relation to ER+ and ER-- breast cancer** ^**a**^**ER+ER--Controls (** ***n*** **)Cases (** ***n*** **)OR(95% CI)Cases (** ***n*** **)OR(95% CI)**Never users4,6328621.00Reference4291.00ReferenceEver users5,4159901.15(1.02 to 1.28)6151.24(1.07 to 1.43)OC recency  \< 5 years ago1,0751831.46(1.18 to 1.81)1311.57(1.22 to 2.03) 5 to 9 years ago544841.16(0.89 to 1.52)641.33(0.97 to 1.82) 10 to 14 years ago5951051.25(0.98 to 1.60)641.12(0.82 to 1.52) 15 to 19 years ago7571531.28(1.04 to 1.58)921.14(0.88 to 1.48) 20 to 24 years ago8591481.01(0.82 to 1.24)971.07(0.83 to 1.37) 25 to 29 years ago7811230.93(0.75 to 1.15)911.41(1.09 to 1.81)  ≥ 30 years ago7951851.14(0.94 to 1.38)711.14(0.85 to 1.51)  *P* trend\<0.010.05OC duration  \< 5 years2,3153671.03(0.89 to 1.19)2601.21(1.01 to 1.44) 5 to 9 years1,6293211.25(1.07 to 1.46)1601.07(0.87 to 1.32) 10 to 14 years1,0102091.35(1.12 to 1.61)1211.43(1.13 to 1.80)  ≥ 15 years458890.98(0.76 to 1.27)731.54(1.15 to 2.06)  *P* trend0.130.05Joint OC exposure (recency and duration)Since last useDuration\< 5 years\< 5 years329391.13(0.78 to 1.62)301.20(0.78 to 1.83)5 to 9 years289451.60(1.12 to 2.28)331.67(1.10 to 2.53)≥ 10 years457991.65(1.27 to 2.15)681.73(1.26 to 2.37)5 to 9 years\< 5 years172221.21(0.75 to 1.94)161.26(0.72 to 2.21)5 to 9 years140301.62(1.05 to 2.52)130.94(0.51 to 1.74)≥ 10 years232320.92(0.62 to 1.38)351.59(1.06 to 2.38)10 to 19 years\< 5 years466661.09(0.82 to 1.47)581.21(0.87 to 1.67)5 to 9 years451871.33(1.02 to 1.73)460.94(0.66 to 1.33)≥ 10 years4351051.41(1.11 to 1.81)521.24(0.90 to 1.72)≥ 20 years\< 5 years1,3442381.02(0.86 to 1.20)1551.23(1.00 to 1.51)5 to 9 years7481571.13(0.92 to 1.38)651.00(0.75 to 1.33)≥ 10 years340610.88(0.65 to 1.19)391.50(1.03 to 2.17)CI, confidence interval; ER, estrogen receptor; OC, oral contraceptive; OR, odds ratio. ^a^ORs adjusted for age, study, time period, geographic region, education, age at menarche, parity, age at first birth, lactation, first-degree family history of breast cancer, menopausal status and age at menopause, duration of female hormone use, body mass index, alcohol consumption, and pack-years of cigarette smoking. *P* trend does not include never users.

In a case--case analysis (data not shown), ever use of OCs (OR = 1.09, 95% CI = 0.92 to 1.29) and OC use within the previous 5 years (OR = 1.08, 95% CI = 0.79 to 1.46) were not associated with ER-- breast cancer, relative to ER+ breast cancer. Increased risk of ER-- breast cancer was associated with long duration (≥15 years) of OC use relative to ER+ cancer: the OR was 1.51 (95% CI = 1.07 to 2.15).

In an analysis stratified by invasive and *in situ* breast cancer (data not shown), results for invasive cancer (1,150 ER+ and 629 ER-- cases) were similar to the overall findings: the ORs for invasive ER+ cancer were 1.14 (95% CI = 1.00 to 1.31) for ever use, 1.41 (95% CI = 1.10 to 1.81) for use within the previous 5 years, and 0.95 (0.69 to 1.30) for duration of 15 years or more; the corresponding estimates for invasive ER-- cancer were 1.36 (95% CI = 1.14 to 1.62), 1.62 (95% CI = 1.20 to 2.20) and 1.59 (1.11 to 2.29), respectively. For *in situ* cancer, based on 255 ER+ cases, risk of ER+ breast cancer was significantly elevated for recent OC use (OR = 1.66, 95% CI = 1.02 to 2.68), but was not associated with long duration of OC use (OR = 0.95, 95% CI = 0.51 to 1.75). There were too few ER-- *in situ* cases (*n* = 43) for an informative analysis.

The relation of OC use to risk of TN breast cancer is presented in Table [3](#Tab3){ref-type="table"}. The OR for recent use of OCs relative to never use was 1.78 (95% CI = 1.25 to 2.53) and risk declined as the interval since last use increased (*P* trend =0.05). Risk increased with increasing duration of OC use, with an OR of 1.62 (95% CI = 1.11 to 2.38) for ≥15 years of use (*P* trend = 0.05). Analyses of a joint variable for duration and recency of use indicated that the increased risk associated with at least 10 years of OC use was statistically significant both for use less than 5 years ago (OR = 1.66, 95% CI = 1.06 to 2.00) and use 5 to 9 years ago (OR = 1.79, 95% CI = 1.04 to 3.07).Table 3**Oral contraceptive use in relation to triple-negative breast cancer** ^**a**^**Controls (** ***n*** **)Cases (** ***n*** **)OR(95% CI)**Never users4,6322131.00ReferenceEver users5,4152821.14(0.93 to 1.40)OC recency  \< 5 years ago1,075661.78(1.25 to 2.53) 5 to 9 years ago544331.37(0.88 to 2.12) 10 to 14 years ago595370.99(0.63 to 1.56) 15 to 19 years ago757471.19(0.83 to 1.72) 20 to 24 years ago859400.85(0.89 to 1.24) 25 to 29 years ago781401.26(0.87 to 1.81)  ≥ 30 years ago795300.91(0.59 to 1.38)  *P* trend0.05OC duration  \< 5 years2,3151171.08(0.84 to 1.39) 5 to 9 years1,629730.99(0.74 to 1.34) 10 to 14 years1,010511.26(0.90 to 1.77)  ≥ 15 years458401.62(1.11 to 2.38)  *P* trend0.05**Joint OC exposure**Since last useDuration\< 5 years\< 5 years329141.31(0.72 to 2.40)5 to 9 years289212.70(1.58 to 4.61)≥ 10 years457301.66(1.06 to 2.60)5 to 9 years\< 5 years17250.89(0.35 to 2.30)5 to 9 years14071.08(0.47 to 2.48)≥ 10 years232191.79(1.04 to 3.07)10 to 19 years\< 5 years466261.12(0.70 to 1.79)5 to 9 years451210.87(0.53 to 1.45)≥ 10 years435271.36(0.87 to 2.11)≥ 20 years\< 5 years1,344721.11(0.83 to 1.49)5 to 9 years748220.67(0.42 to 1.06)≥ 10 years340151.14(0.65 to 2.00)CI, confidence interval; OC, oral contraceptive; OR, odds ratio. ^a^ORs adjusted for age, study, time period, geographic region, education, age at menarche, parity, age at first birth, lactation, first-degree family history of breast cancer, menopausal status and age at menopause, duration of female hormone use, body mass index, alcohol consumption, and pack-years of cigarette smoking. *P* trend does not include never users.

In analyses stratified by age (\<40 years, 40 to 49 years, ≥50 years), recent and long-duration OC use were associated with increased risk of breast cancer in every age group (Table [4](#Tab4){ref-type="table"}). The interaction was not statistically significant for OC recency or duration (*P* interaction = 0.75 and *P* interaction = 0.77, respectively).Table 4**Oral contraceptive use in relation to breast cancer risk, stratified by age** ^**a**^**Age \<40Age 40 to 49Age ≥50Controls (** ***n*** **)Cases (** ***n*** **)OR(95% CI)Controls (** ***n*** **)Cases (** ***n*** **)OR(95% CI)Controls (** ***n*** **)Cases (** ***n*** **)OR(95% CI)**Never users351851.00Reference1,0222721.00Reference3,2599341.00ReferenceEver users7962391.33(0.97 to 1.81)2,0575841.18(0.98 to 1.42)2,5627821.15(1.01 to 1.30)OC recency  \< 5 years ago4821301.55(1.09 to 2.19)4821491.60(1.23 to 2.07)111351.50(0.99 to 2.28) 5 to 9 years ago185531.20(0.77 to 1.86)292741.18(0.86 to 1.63)94210.95(0.57 to 1.58)  ≥ 10 years ago154561.04(0.67 to 1.61)1,2823611.07(0.88 to 1.31)2,3517161.14(1.00 to 1.29)  *P* trend0.02\<0.010.45OC duration  \< 5 years342841.18(0.81 to 1.70)8352251.12(0.90 to 1.40)1,1383181.08(0.92 to 1.27) 5 to 9 years239791.40(0.95 to 2.06)6291601.06(0.83 to 1.35)7612421.20(1.00 to 1.44)  ≥ 10 years215761.48(0.99 to 2.20)5931991.39(1.10 to 1.76)6602171.20(0.99 to 1.45)  *P* trend0.170.110.26CI, confidence interval; OC, oral contraceptive; OR, odds ratio. ^a^ORs adjusted for age, study, time period, geographic region, education, age at menarche, parity, age at first birth, lactation, first-degree family history of breast cancer, menopausal status and age at menopause, duration of female hormone use, body mass index, alcohol consumption, and pack-years of cigarette smoking. *P* trend does not include never users.

In analyses stratified by menopausal status (Table [5](#Tab5){ref-type="table"}), ORs were higher in premenopausal women, but there was not a statistically significant interaction (*P* interaction = 0.16 for recency, *P* interaction = 0.06 for duration). Breast cancer risk was elevated for recent OC use in both nulliparous and parous women (Table [5](#Tab5){ref-type="table"}): among nulliparous women the OR for OC use within the previous 5 years was 1.37 (95% CI = 0.98 to 1.92), and the corresponding OR for parous women was 1.55 (95% CI = 1.26 to 1.90) (*P* interaction = 0.08). Long duration of OC use was associated with breast cancer among parous women, but not among nulliparous women (Table [5](#Tab5){ref-type="table"}). The interaction was not significant (*P* = 0.42).Table 5**Oral contraceptive use in relation to breast cancer risk, stratified by menopausal status and parity** ^**a**^**Controls (** ***n*** **)Cases (** ***n*** **)OR(95% CI)Controls (** ***n*** **)Cases (** ***n*** **)OR(95% CI)Premenopausal womenPostmenopausal women**Never users1,3713631.00Reference2,9038541.00ReferenceEver users2,6677671.24(1.05 to 1.45)2,1847031.16(1.01 to 1.33)OC recency  \< 5 years ago9372731.54(1.25 to 1.90)90191.02(0.59 to 1.76) 5 to 9 years ago4041131.31(1.01 to 1.72)99210.85(0.50 to 1.44)  ≥ 10 years ago1,3243801.08(0.90 to 1.30)1,9896541.17(1.02 to 1.34)  *P* trend\<0.010.39OC duration  \< 5 years1,0662761.11(0.91 to 1.35)9923011.14(0.96 to 1.36) 5 to 9 years8182171.14(0.92 to 1.41)6482221.24(1.02 to 1.50)  ≥ 10 years7822741.53(1.25 to 1.88)5421751.09(0.88 to 1.34)  *P* trend\<0.010.83**Nulliparous womenParous women**Never users9172441.00Reference3,7061,0461.00ReferenceEver users1,2302671.09(0.87 to 1.38)4,1831,3381.21(1.08 to 1.35)OC recency  \< 5 years ago406931.37(0.98 to 1.92)6692111.55(1.26 to 1.90) 5 to 9 years ago160220.77(0.46 to 1.29)3831261.39(1.08 to 1.77)  ≥ 10 years ago6631511.05(0.81 to 1.36)3,1239821.15(1.03 to 1.29)  *P* trend0.16\<0.01OC duration  \< 5 years438891.06(0.79 to 1.44)1,8755381.11(0.97 to 1.27) 5 to 9 years361761.08(0.78 to 1.50)1,2684051.22(1.05 to 1.42)  ≥ 10 years4311021.13(0.84 to 1.52)1,0373901.37(1.17 to 1.60)  *P* trend0.610.01CI, confidence interval; OC, oral contraceptive; OR, odds ratio. ^a^ORs adjusted for age, study, time period, geographic region, education, age at menarche, parity, age at first birth, lactation, first-degree family history of breast cancer, menopausal status and age at menopause, duration of female hormone use, body mass index, alcohol consumption, and pack-years of cigarette smoking, where appropriate. *P* trend does not include never users. Women who were missing menopausal status (*n* = 1,218) were excluded from the analysis that stratified on this variable. Women who were missing parity (*n* = 13) were excluded from the analysis that stratified on this variable.

Recent and long-duration OC use were associated with larger increases in breast cancer risk among women who were overweight or obese than among women with body mass index \<25 kg/m^2^ (Table [6](#Tab6){ref-type="table"}). The interaction was significant for recent OC use (*P* interaction = 0.04), but not for duration of OC use (*P* interaction = 0.16).Table 6**Oral contraceptive use in relation to breast cancer risk, stratified by body mass index** ^**a**^**BMI \<25.0 kg/m** ^**2**^**BMI 25.0 to 29.9 kg/m** ^**2**^**BMI ≥30.0 kg/m** ^**2**^**Controls (** ***n*** **)Cases (** ***n*** **)OR(95% CI)Controls (** ***n*** **)Cases (** ***n*** **)OR(95% CI)Controls (** ***n*** **)Cases (** ***n*** **)OR(95% CI)**Never users9312311.00Reference1,5033871.00Reference2,0966371.00ReferenceEver users1,3713501.09(0.88 to 1.35)1,7465211.13(0.95 to 1.35)2,2117071.26(1.09 to 1.45)OC recency  \< 5 years ago361871.22(0.87 to 1.71)3201111.58(1.16 to 2.14)3771121.57(1.19 to 2.08) 5 to 9 years ago156320.87(0.55 to 1.38)175461.06(0.71 to 1.58)204691.71(1.23 to 2.37)  ≥ 10 years ago8512301.09(0.87 to 1.38)1,2483631.09(0.90 to 1.31)1,6275181.17(1.01 to 1.36)  *P* trend0.170.050.04OC duration  \< 5 years5661351.05(0.80 to 1.37)7261981.12(0.90 to 1.39)9862781.09(0.91 to 1.30) 5 to 9 years4081091.11(0.83 to 1.49)5441521.04(0.82 to 1.33)6512131.34(1.09 to 1.64)  ≥ 10 years3971051.11(0.83 to 1.50)4761711.27(1.00 to 1.61)5712121.48(1.20 to 1.82)  *P* trend0.670.48\<0.01BMI, body mass index; CI, confidence interval; OC, oral contraceptive; OR, odds ratio. ^a^ORs adjusted for age, study, time period, geographic region, education, age at menarche, parity, age at first birth, lactation, first-degree family history of breast cancer, menopausal status and age at menopause, duration of female hormone use, body mass index, alcohol consumption, and pack-years of cigarette smoking. *P* trend does not include never users.

Figure [1](#Fig1){ref-type="fig"} presents study-specific estimates and ORs for recent (within previous 5 years) and long-term (≥10 years) OC use in relation to ER+ and ER-- breast cancer computed from a meta-analysis with a random-effects model. The *P* value for heterogeneity was 0.57 or greater for all comparisons, indicating no statistically significant heterogeneity.Figure 1**Results from meta-analysis of oral contraceptive recency and duration in relation to breast cancer subtype.** Odds ratios and 95% confidence intervals from the full model by study and from a random-effects meta-analysis for oral contraceptive (OC) recency in relation to ER+ **(A)** and ER-- **(B)** breast cancer and OC duration in relation to ER+ **(C)** and ER-- **(D)** breast cancer. BWHS, Black Women's Health Study; CBCS, Carolina Breast Cancer Study; ER, estrogen receptor; WCHS, Women's Circle of Health Study.

Discussion {#Sec10}
==========

Both recent OC use and long duration of OC use were associated with increased risk of breast cancer in this study of African American women. The positive associations were observed for ER+, ER--, and TN breast cancer. ORs were highest for TN breast cancer: women who had used OCs in the past 5 years were estimated to have a 78% increased risk of TN breast cancer and those who had used OCs for at least 15 years had a 62% increase.

While some studies have found no association of recent OC use with overall breast cancer risk \[[@CR2],[@CR3],[@CR5],[@CR38],[@CR39]\], many others have reported that recent OC users experience an increase in risk, which has varied from 24% to 60% \[[@CR1],[@CR6],[@CR9],[@CR11],[@CR12],[@CR40]\]. The present findings are similar in magnitude to the previous positive associations. A collaborative analysis of 54 studies concluded that the increased risk of breast cancer associated with OC use disappears by 10 years after last use \[[@CR1]\]. In a large case--control study that included African American women, no association was observed for long intervals (≥20 years) since last OC use \[[@CR2],[@CR3]\]. However, in the present study of African American women, an increased risk was present up to 15 to 19 years after last use for ER+ cancer and after an even longer interval for ER-- cancer. Results for duration of use are less consistent in the literature, with some studies reporting no association with long duration \[[@CR2],[@CR3],[@CR25],[@CR39],[@CR41]-[@CR43]\] while others observed a positive association \[[@CR4]-[@CR13]\]. In the present study, long duration use appeared to be more strongly associated with ER-- cancer than with ER+ cancer.

There are few previous studies of OC use with molecular subtype of breast cancer. Five studies found associations of OC use with both ER+ and ER-- breast cancer \[[@CR4],[@CR8]-[@CR10],[@CR12]\]. One study found an association for only ER+ breast cancer \[[@CR24]\] and two found an association for only ER-- breast cancer \[[@CR23],[@CR44]\], while two other studies found no association for either subtype \[[@CR45],[@CR46]\]. Of the studies that could evaluate TN or basal-like breast cancer, three found a positive association \[[@CR10],[@CR23],[@CR26],[@CR47]\] while two others observed no association \[[@CR2],[@CR25]\].

Combination OCs contain estrogens and progestins and have been found to increase circulating levels of estradiol \[[@CR48],[@CR49]\]. A potential mechanism for increased risk of breast cancer with recent OC use is through estrogen-induced or progesterone-induced proliferation of breast cancer cells \[[@CR50],[@CR51]\], which could cause progression of breast cancer. This mechanism may not be applicable for ER-- breast cancer. Estrogens may also promote angiogenesis and stromal cell recruitment \[[@CR52]\], which would be relevant for both ER+ and ER-- breast cancer. OCs may also cause epigenetic changes, such as a decrease in DNA methylation \[[@CR53]\]. DNA hypomethylation may be associated with tumor progression and metastasis \[[@CR54]\] and represents another potential mechanism for the relation of OC use to breast cancer risk. It has been suggested that tumors regress after cessation of use of menopausal hormone supplements \[[@CR55],[@CR56]\]. The tumors associated with menopausal hormone use are ER+. Whether tumor regression occurs after cessation of OC use is unknown, but this mechanism might not explain results for ER-- breast cancer.

Few studies have examined potential effect modification of the relation of OC use to breast cancer risk by age \[[@CR9],[@CR23],[@CR57]\]. Of these, some studies have observed a stronger association with risk among younger women than among older women, but this difference has generally not been statistically significant \[[@CR4],[@CR26],[@CR58],[@CR59]\]. In a report from the BWHS, age did not significantly modify the association of OC use with breast cancer subtype \[[@CR9]\]. In a Washington state case--control study, ORs for OC use were higher among women under age 40, but there was not a significant interaction by age \[[@CR23]\]. In a multisite case--control study, ORs for OC use were significantly higher among women under age 35 and age 35 to 44 years, compared with women age 45 years and older \[[@CR57]\]. In the present study, ORs were somewhat higher in the youngest age group, but there was not a significant interaction. ORs were also higher among premenopausal women than among postmenopausal women, but, again, the interaction was not statistically significant and there were few recent users among the postmenopausal women. Previous studies have observed associations of OC use with breast cancer risk in both premenopausal and postmenopausal women \[[@CR8],[@CR45]\].

Differences in risk of breast cancer by age or menopausal status could reflect changes in OC formulations. The estrogen and progestin composition of OCs has varied, with declining doses of hormones and new types of progestin introduced over time \[[@CR40],[@CR60],[@CR61]\]. There is no clear evidence that some formulations carry higher risk than others \[[@CR5],[@CR62]-[@CR64]\]. We were not able to evaluate formulation, as we did not have detailed information on OC type used. Thus, we cannot rule out the possibility that associations vary according to OC formulation. However, while younger women are more likely to use newer OC formulations, our findings did not vary significantly by strata of age or birth cohort in the present study. Moreover, estimates were similar across the studies, which were conducted in different time frames ranging from 1993 to present.

The associations of OC use with breast cancer risk in the present study were stronger among overweight and obese women. No previous studies have assessed whether an association of breast cancer risk with recent or long duration of OC use is modified by body mass index. This finding is particularly important given the high prevalence of obesity in African American women \[[@CR65]\]. Obesity may alter the pharmacokinetic parameters of OCs, which could prolong exposure to estrogen in obese women due to an increase in the half-life of circulating estradiol, an increase in the rate of OC absorption, or an increase in bioavailability of the chemical compounds in the OCs \[[@CR66]-[@CR68]\].

The present analysis is the largest yet conducted of OC use in relation to specific subtypes of breast cancer among African American women. It allowed for informative assessment of associations within subtype overall and within some strata of interest. However, statistical power in some subanalyses was limited. Numerous important risk factors for breast cancer were controlled in the analyses. While the studies that contributed to the present analyses differed in study design and in population characteristics, a meta-analysis found no significant heterogeneity in the results. In addition, results on other risk factors, including parity and body size, have been similar across the individual studies \[[@CR8],[@CR21],[@CR69]-[@CR72]\]. Thus, the results are likely to be generalizable to other African American women. A limitation was that the classification by molecular subtype was based on the particular methods used in each pathology laboratory in the large number of hospitals from which the cases were derived. However, it is unlikely that misclassification will have been related to the OC use of cases. We did not have data to validate self-reported OC use, but validation studies have shown that OC use is generally well reported \[[@CR5],[@CR73],[@CR74]\]. We did not have detailed information on OC type used, and therefore cannot rule out variations in associations by OC formulation.

Conclusions {#Sec11}
===========

In sum, our findings suggest that recent OC use, particularly of long duration, is associated with increased risk of ER+, ER--, and TN breast cancer in African American women, with possibly a stronger relation with TN breast cancer. Increases in risk associated with OC use were apparent for up to 15 years or more after cessation of use. The association with OC use was most pronounced among overweight and obese women. Research is needed to investigate the mechanisms by which obesity may further increase the breast cancer risk associated with OC use.
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